TABLE 3

Randomised phase III trials comparing tyrosine kinase inhibitors versus chemotherapy as first-line treatment for sensitive epidermal growth factor receptor-mutated lung cancer

First author [ref.]	Treatment arm	Patients n	Objective response %	p-value	Median progression-free survival months	p-value	Median survival months	p-value
Maemondo [9] and Inoue [10]	Gefitinib	114	73	<0.001	10.8	<0.001	27.7	0.483
Maemondo [9] and Inoue [10]	Carboplatin+ paclitaxel	114	30	<0.001	5.4	<0.001	26.6	0.483
Mitsudomi [11]	Gefitinib	86	62	<0.0001	9.2	<0.0001	Not reached	0.211
Mitsudomi [11]	Cisplatin+ docetaxel	86	32	<0.0001	6.3	<0.0001	30.9	0.211
Zhou [12]	Erlotinib	83	82	<0.0001	13.1	<0.0001	22.7	ns
Zhou [12]	Gemcitabine+ carboplatin	82	36	<0.0001	4.6	<0.0001	28.9	ns
Rosell [13]	Erlotinib	86	58	<0.0001	9.7	<0.0001	19.3	0.87
Rosell [13]	Standard chemotherapy	87	15	<0.0001	5.2	<0.0001	19.5	0.87
Sequist [14]	Afatinib	230	56	0.001	11.1	0.001	Not reached	0.60
Sequist [14]	Cisplatin+ pemetrexed	115	23	0.001	6.9	0.001	Not reached	0.60
Wu [15]	Afatinib	242	67	<0.0001	11	<0.0001	22.1	0.76
Wu [15]	Gemcitabine+ cisplatin	122	23	<0.0001	5.6	<0.0001	22.2	0.76

ns: nonsignificant.